Drug Trial Radar · NCT06584058
HPP737 Substance Balance Study in Human
Last checked: Nov 19, 2026Latest source record: Sep 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
8
Planned (sponsor's estimate)
Start
Aug 30, 2024
Primary completion
Jul 30, 2025
Study completion Aug 30, 2025
Sponsor
- Lead sponsor
- Newsoara Biopharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 4, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Main research purpose 1. Quantitative analysis of the total amount of radioactivity in excreta (urine and feces) of male healthy subjects after oral administration of \[14C\]HPP737, to obtain the cumulative excretion rate and main excretion routes of human radioactivity; 2. To identify the main metabolites in the offspring of \[14C\]HPP737 in healthy male subjects, and to determine the main biotransformation pathway and main metabolite structure; 3. To investigate the distribution of total radioactivity in whole blood and plasma and the pharmacokinetics of total plasma radioactivity in healthy male subjects after a single oral administration of \[14C\]HPP737. Participants will: 1. Take Investigational product once 2. Stay in the clinic about 7 days for checkups and tests 3. Report their symptoms
Conditions
- Psoriasis
Interventions
HPP737Drug
\[14C\]HPP737 oral preparation, 20mg(150μCi), once
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cmax (peak concentration)Time frame: Up to 12 months
- Tmax (peak time)Time frame: Up to 12 months
- AUC0-T (area under drug time curve)Time frame: Up to 12 months
- AUC0-∞ (area under drug time curve)Time frame: Up to 12 months
- t1/2 (elimination half-life)Time frame: Up to 12 months
- CL/F (apparent clearance)Time frame: Up to 12 months
- Vd/F (apparent volume of distribution)Time frame: Up to 12 months
- MRT (mean residence time)Time frame: Up to 12 months
- Cumulative drug excretion(Urine)Time frame: Up to 12 months
- Cumulative drug excretion(stool)Time frame: Up to 12 months
- Major metaboliteTime frame: Up to 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.